Botanical species · safety record

Lolium temulentum

The EFSA Compendium of Botanicals holds 2 constituent measurements and 4 adverse-effect records for Lolium temulentum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Lolium temulentum L.

2Constituent measurements

4Safety records

4Cited sources

4Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 4 licensed products naming Lolium temulentum as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Ripe spikelets

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Pyrrolizidine alkaloids	Seed	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Pyrrolizidine alkaloids	Aerial part of plants	Solvent extraction	—	Unspecified	Resolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Neurotoxicity	Neurologic: central nervous system	Seed	Solvent extraction	Rat (as animal)	Acute toxicity	Resolve DOI
Pulmonary and cardiac	Respiratory	Seed	—	Cattle (as animal)	Not reported	Resolve DOI
Systemic	Heart	—	Solvent extraction	Rabbit (as animal)	Other	Resolve DOI
Systemic	Neurologic	—	Solvent extraction	Human (as organism)	Case report	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Hammouda, F.M., Rizk, A.M., El-Missiry, M.M., Ghaleb, H.A., Madkour, M.K., Pohland, A.E., Wood, G. Poisonous plants contaminating edible ones and toxic substances in plant foods IV. Phytochemistry and toxicity of lolium temulentum. Pharmaceutical biology, 1988, vol. 26, no. 4, p. 240-245. DOI
Al-Qura'n, S. Ethnobotanical survey of folk toxic plants in southern part of Jordan. Toxicon, 2005, vol. 46, no. 2, p. 119-129. DOI
Antze, P. Lolium temulentum in pharmakognostischer, chemischer, physiologischer und toxikologischer Hinsicht. Archiv f�r experimentelle pathologie und pharmakologie, 1891, vol. 28, no. 1-2, p. 126-144. DOI
Roeder, E., Wiedenfeld, H. Plants containing pyrrolizidine alkaloids used in the Traditional Indian Medicine - including Ayurveda. PHARMAZIE, 2013, vol. 68, no. 2, p. 83-92. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature